Dr. Young is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
34490 Bob Hope Dr
Rancho Mirage, CA 92270
Summary
- Dr. David Young is an oncologist based in Rancho Mirage, CA, specializing in hematologic oncology with extensive experience in conditions such as amyloidosis, myelodysplasia, myelofibrosis, and multiple myeloma. He completed his fellowship in hematology and medical oncology at the University of California Davis Health and Los Angeles County-Harbor-UCLA Medical Center after finishing his residency and internship in internal medicine at San Joaquin General Hospital. A graduate of the University of Illinois College of Medicine.
Retired
Education & Training
- University of California Davis HealthFellowship, Hematology and Medical Oncology, 1988 - 1989
- Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 1986 - 1988
- San Joaquin General HospitalResidency, Internal Medicine, 1980 - 1983
- San Joaquin General HospitalInternship, Transitional Year, 1979 - 1980
- University of Illinois College of MedicineClass of 1979
Certifications & Licensure
- CA State Medical License 1980 - 2026
- AR State Medical License 1999 - 2001
- TN State Medical License 1998 - 2001
- CO State Medical License 1983 - 1987
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2014
Clinical Trials
- A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Start of enrollment: 2020 Feb 06
Publications & Presentations
Press Mentions
- PROCESSA PHARMACEUTICALS : ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117 (Form 8-K)June 17th, 2021
- Processa Pharmaceuticals Enters into a Licensing Agreement with Ocuphire Pharma, Inc., for the Development of Rx-3117June 17th, 2021
- Processa Pharmaceuticals Entered into a Contingent Precedent in-Licensing Agreement with Elion Oncology for the Development of Eniluracil (pcs6422) for the Treatment of Advanced Gastrointestinal...August 27th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: